Mangoceuticals, Inc. (MGRX)

Mangoceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.62	0.73	0.01	-
Revenue Growth (YoY)	-15.81%	8083.16%	-	-
Cost of Revenue	0.24	0.3	0	-
Gross Profit	0.38	0.43	0	-
Selling, General & Admin	5.54	6.39	2	0.07
Operating Expenses	8.62	8.55	2	0.07
Operating Income	-8.24	-8.12	-1.99	-0.07
Interest Expense	-0.01	-	-0.01	-0
Interest & Investment Income	-	0.01	-	-
Other Non Operating Income (Expenses)	-0.45	-1.1	-	-
Pretax Income	-8.71	-9.21	-2	-0.07
Earnings From Continuing Operations	-8.71	-9.21	-2	-0.07
Minority Interest in Earnings	0	-	-	-
Net Income	-8.71	-9.21	-2	-0.07
Preferred Dividends & Other Adjustments	0.87	-	-	-
Net Income to Common	-9.58	-9.21	-2	-0.07
Shares Outstanding (Basic)	2	1	1	1
Shares Outstanding (Diluted)	2	1	1	1
Shares Change (YoY)	84.23%	49.22%	34.98%	-
EPS (Basic)	-4.84	-8.58	-2.78	-
EPS (Diluted)	-4.84	-8.58	-2.78	-
Free Cash Flow	-4.86	-7	-1.39	-0.07
Free Cash Flow Per Share	-2.46	-6.52	-1.93	-0.13
Gross Margin	61.70%	58.99%	54.26%	-
Operating Margin	-1337.90%	-1109.84%	-22279.70%	-
Profit Margin	-1555.26%	-1259.40%	-22352.11%	-
Free Cash Flow Margin	-789.74%	-957.07%	-15545.59%	-
EBITDA	-7.51	-8.09	-1.99	-
D&A For EBITDA	0.73	0.02	0	-
EBIT	-8.24	-8.12	-1.99	-0.07

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q